Mesothelioma of the tunica vaginalis

Summary

Mesothelioma of the tunica vaginalis (MONDO:0975890) is a disease. A subtype of malignant mesothelioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Cases/families		289	Worldwide	Validated
Point prevalence	<1 / 1 000 000		Worldwide	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	mesothelioma of the tunica vaginalis
Mondo ID	MONDO:0975890
Orphanet	685010
UMLS	C3494988
MedGen	782172
GARD	0027408
Is cancer (heuristic)	no

Disease family

This is a subtype of malignant mesothelioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant mesothelioma › mesothelioma of the tunica vaginalis

Related subtypes (10): ovarian malignant mesothelioma, malignant pericardial mesothelioma, malignant pleural mesothelioma, malignant peritoneal mesothelioma, malignant epithelioid mesothelioma, malignant biphasic mesothelioma, sarcomatoid mesothelioma, localized pleural mesothelioma, diffused pleural mesothelioma, pleural mesothelioma in situ

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.